SCHEMBL24099161

SCHEMBL24099161

O=C(CCCCN1C(=O)c2ccccc2C1=O)c1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
HPGD P15428 4/20 0.64
HSD17B10 Q99714 2/20 0.60
KMT2A Q03164 1/20 0.60
POLB P06746 1/20 0.57
HDAC8 Q9BY41 3/20 0.56
HDAC3 O15379 2/20 0.56
HDAC4 P56524 2/20 0.56
HDAC1 Q13547 2/20 0.56
HDAC7 Q8WUI4 2/20 0.56
HDAC2 Q92769 2/20 0.56
HDAC10 Q969S8 2/20 0.56
HDAC11 Q96DB2 2/20 0.56
HDAC6 Q9UBN7 2/20 0.56
HDAC9 Q9UKV0 2/20 0.56
HDAC5 Q9UQL6 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
ACHE P22303 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24099262 0.99 ALDH1A1 (0.67) ALDH1A1HPGDHSD17B10KMT2APOLB
SCHEMBL7345361 0.90 SMN1; SMN2 (0.63) ALDH1A1HPGDHSD17B10KMT2APOLB
SCHEMBL17267467 0.88 HDAC8 (0.61) ALDH1A1HPGDHSD17B10KMT2AHDAC8
SCHEMBL8373956 0.84 TDP1 (0.59) ALDH1A1HPGDKMT2AHDAC8HDAC3
SCHEMBL8562369 0.83 SMN1; SMN2 (0.56) ALDH1A1HPGDHSD17B10KMT2AHDAC8
SCHEMBL28882520 0.83 ALDH1A1 (0.50) ALDH1A1HPGDHSD17B10KMT2APOLB
SCHEMBL24798048 0.82 ALDH1A1 (0.54) ALDH1A1HPGDHSD17B10KMT2AHDAC8
SCHEMBL14288291 0.82 NPC1 (0.69) ALDH1A1HSD17B10KMT2APOLBNPC1
SCHEMBL696173 0.80 GSK3B (0.71) ALDH1A1HPGDHSD17B10KMT2APOLB
SCHEMBL10366277 0.78 ALDH1A1 (0.51) ALDH1A1HPGDHSD17B10KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4165023-A1 INHIBITORS OF APOL1 AND USE OF THE SAME Vertex Pharmaceuticals Incorporated (US) 2023-04-19 EP disclosed
CN-115867532-A Inhibitors of APOL1 and uses thereof 弗特克斯药品有限公司 2023-03-28 CN disclosed
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-01-19 US disclosed
WO-2021252849-A1 INHIBITORS OF APOL1 AND USE OF THE SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, NPC1L1 ALDH1A1 1965/4885HPGD 2373/4885HSD17B10 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.